Clinical Trials
12 trialsNCT06282991 2026-03-10
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
Completed
NCT03909971 2025-11-05
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Pfizer
Phase 2 Completed
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT04362072 2025-06-11
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Pfizer
Phase 4 Completed
NCT04111705 2025-04-01
ORAKLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT04541706 2024-12-20
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Pfizer
Phase 4 Completed
NCT01970865 2024-08-12
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Pfizer
Phase 1/2 Completed
NCT03546894 2024-07-15
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
Takeda
Completed
NCT04541407 2023-05-16
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
University of Colorado, Denver
Phase 1 Completed
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed
NCT05167500 2023-03-30
LORLAPULM
Fundación GECP
Completed